Efferon, an Austrian healthtech company founded in 2016, has reached a significant milestone in its development of extracorporeal blood-purification devices designed to treat sepsis and septic shock. The Vienna-based startup’s paediatric device, branded as Efferon NEO, obtained CE MDR certification in April 2026, marking it as the first multimodal extracorporeal blood-purification device approved for paediatric use in Europe.
This regulatory achievement follows the company’s adult device receiving CE MDR approval in April 2024, establishing Efferon’s technology platform across both patient populations. The devices work by removing bacterial toxins and inflammatory mediators from the bloodstream, addressing a critical need in intensive care settings where sepsis remains a leading cause of mortality.
Growing Clinical Adoption and Revenue
Efferon’s technology has already demonstrated substantial real-world traction. The devices have been deployed in more than 25,000 treatments across 44 countries, generating over €1 million in revenue. This widespread adoption indicates growing clinical acceptance of the company’s approach to managing one of medicine’s most challenging conditions.
According to Dima Romashin, a representative of the company, the technology fulfils a specific clinical purpose. “We’re helping to interrupt the inflammatory process so that during those first critical days, the patient can be stabilised and the other therapies have time to work,” Romashin explained. This perspective underscores how Efferon’s devices function within broader sepsis treatment protocols rather than replacing existing interventions.
Expansion Into New Markets and Applications
With European regulatory approvals secured for both adult and paediatric indications, Efferon is now directing its efforts toward international expansion. The company is preparing a Humanitarian Device Exemption filing for the United States market, a regulatory pathway designed for devices addressing rare or life-threatening conditions with limited treatment alternatives.
Beyond North America, Efferon is targeting China as a growth market, recognising the substantial patient populations in Asia-Pacific regions that could benefit from its technology.
The startup is also diversifying its product portfolio beyond acute sepsis treatment. Efferon is developing an outpatient solution aimed at addressing post-sepsis complications and chronic inflammatory conditions—a recognition that sepsis survivors frequently face prolonged recovery periods and ongoing health challenges.
Broader Ecosystem Context
Efferon’s progression reflects a broader trend within the European healthtech sector, where companies are increasingly targeting critical care applications with regulated medical devices. The startup’s ability to secure CE MDR certification for both adult and paediatric devices demonstrates the European regulatory pathway’s capacity to support innovation in complex therapeutic areas. With sepsis affecting millions globally and carrying substantial mortality rates even in developed healthcare systems, the expansion of proven treatment technologies represents a meaningful advancement for patient care within European hospitals and beyond.